Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.
Where Will Viking Therapeutics Be in 3 Years? Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.
Why Viking Therapeutics Stock Popped Again Today Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock.
Why Viking Therapeutics Stock Popped Today 2025 is the year we learn whether Viking Therapeutics stock will be a winner.
Viking Therapeutics Stock May Struggle After As-Expected Report Viking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard.
Viking Therapeutics Stock Dips After Q1 EPS Miss: Details Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the report.
A Look At Viking Therapeutics VKTX While we wait for the earnings report to be posted along with the forward guidance predictions, the chart looks interesting.
Eli Lilly Stock Rockets On Weight-Loss Pill Progress Eli Lilly's pill-form weight loss drug cansdidate cleared one of several Phase III hurdles.
